Lexicon's sotagliflozin improves cardiac function in mouse study of hypertrophic cardiomyopathy
LXRX•Lexicon highlighted two published preclinical studies of sotagliflozin: one found improved heart structure and function in mice with hypertrophic cardiomyopathy, while the other found reduced platelet activation and clot formation. Topline results from the Phase 3 SONATA-HCM trial are expected in the first quarter of 2027.
1. Preclinical study results
Lexicon highlighted two published preclinical studies of sotagliflozin. One found improved heart structure and function in mice with hypertrophic cardiomyopathy; the other found reduced platelet activation and clot formation in human blood samples and animal models without impairing normal clotting, unlike empagliflozin.
2. Phase 3 trial
The ongoing Phase 3 SONATA-HCM trial covers symptomatic obstructive and non-obstructive hypertrophic cardiomyopathy. Topline results are expected in the first quarter of 2027.
